Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKTOR and Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT07558733Phase 2Recruiting
- Sponsor
- Faeth Therapeutics
- Start
- Apr 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib, serabelisib in breast cancer, sponsored by Faeth Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
sapanisertibserabelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07558733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558733.